Is a new diabetes drug safer for the heart than an old one?
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 582 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 582 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Journal
The New England journal of medicine
Year
2025
Authors
Stephen J. Nicholls, I. Pavo, Deepak L. Bhatt, J. Buse, Stefano Del Prato, S. Kahn, A. M. Lincoff, Darren K. Mcguire, Debra Miller, Michael A. Nauck, H. Nishiyama, Steven E. Nissen, N. Sattar, G. Weerakkody, R. Wiese, B. Zinman, S. Zoungas, Jan N. Basile, Melanie J. Davies, F. Giorgino, M. Kellerer, L. Ji, T. Várkonyi, V. Menon, J. Broder, Alan Herschtal, D. D’Alessio
Related Content
Claims (6)
In adults with type 2 diabetes and heart disease, a weekly injection of tirzepatide reduces the risk of heart-related death, heart attack, or stroke just as effectively as another drug called dulaglutide, even though tirzepatide leads to greater weight loss and better blood sugar control.
Among adults with type 2 diabetes and heart disease, tirzepatide was associated with a 16% lower risk of death from any cause over four years compared to dulaglutide, based on statistical analysis of patient outcomes.
Over 36 months, tirzepatide lowered body weight and blood sugar levels more than dulaglutide in adults with type 2 diabetes and heart disease, while both drugs had similar effects on cardiovascular safety.
In adults with type 2 diabetes and heart disease, the rates of severe low blood sugar and pancreatitis are about the same for tirzepatide and dulaglutide, meaning neither drug appears to cause more of these serious side effects than the other.
In patients with type 2 diabetes and heart disease, tirzepatide lowers the combined risk of serious heart and kidney events by 16% compared to dulaglutide.